Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ

Michaela R Reagan, F Philipp Seib, Douglas W McMillin, Elizabeth K Sage, Constantine S Mitsiades, Sam M Janes, Irene M Ghobrial, David L Kaplan

Research output: Contribution to journalArticle

43 Citations (Scopus)


Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based delivery system for sustained therapeutic cell release that capitalizes on the tumor-homing properties of mesenchymal stem cells (MSCs) and their ability to express genetically-introduced therapeutic genes.
Original languageEnglish
Pages (from-to)273-282
Number of pages10
JournalJournal of breast cancer
Issue number3
Publication statusPublished - Sep 2012


  • breast neoplasms
  • mesenchymal stem cells
  • tissue engineering
  • tissue therapy
  • TNF-related apoptosis-inducing ligand

Cite this